Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seagen Inc
(NQ:
SGEN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seagen Inc
< Previous
1
2
3
4
5
Next >
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
September 28, 2021
From
Seagen Inc.
Via
Business Wire
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
September 27, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
September 20, 2021
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021
From
Genmab A/S
Via
Business Wire
Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021
From
Seagen Inc.
Via
Business Wire
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
September 19, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
September 08, 2021
From
Seagen Inc.
Via
Business Wire
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
August 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Reports Second Quarter 2021 Financial Results
July 29, 2021
From
Seagen Inc.
Via
Business Wire
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
July 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
July 08, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting
June 03, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021
From
Seagen Inc.
Via
Business Wire
Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
May 19, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Reports First Quarter 2021 Financial Results
April 29, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting
April 29, 2021
From
Seagen Inc.
Via
Business Wire
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
April 19, 2021
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
April 09, 2021
From
Genmab A/S
Via
Business Wire
Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
April 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Data from Novel Targeted Therapies at AACR
April 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021
April 07, 2021
From
Seagen Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.